Glucocorticoid Receptor 

 186 Products   186 Products   1696 Diseases   95004 News 


«12...8081828384858687888990...10641065»
  • ||||||||||  dexamethasone / Generic mfg.
    Dexamethasone in herpes encephalitis: are all votes in? (Hall H) -  Feb 1, 2024 - Abstract #ECCMID2024ECCMID_1217;    
    Systemic hydrocortisone started in the second week after birth in ventilator-dependent infants born very preterm was not found to be associated with significant differences in brain development compared with placebo treatment. Sponsored By ESCMID Study Group for Infectious Diseases of the Brain (ESGIB)
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS
    SY207 - New treatments for CNS infections (Hall H) -  Feb 1, 2024 - Abstract #ECCMID2024ECCMID_1216;    
    Progressive multifocal leukoencephalopathy used to be a uniformly deadly disease, but the introduction of checkpoint inhibitor treatments (nivolumab and pembrolizumab) presented a new way of boosting the immune system and clear the JC- virus. In this session we will discuss these two treatments in CNS infections.
  • ||||||||||  dexamethasone / Generic mfg.
    Trial completion:  Dexhia: Efficacy of Soluble Dexamethasone in Refractory Sciatica (clinicaltrials.gov) -  Feb 1, 2024   
    P3,  N=109, Completed, 
    In conclusion, second-line treatment with Dara-Ixa-dex in patients with RRMM pre-treated with a lenalidomide-based regimen resulted in rapid responses along with a favorable effect on bone metabolism. Recruiting --> Completed
  • ||||||||||  dexamethasone / Generic mfg., ketamine / Generic mfg.
    Journal:  Editorial Commentary: The Addition of the Pericapsular Nerve Group Block Leads to Reduced Pain Up to 24 (Pubmed Central) -  Jan 31, 2024   
    Our current multimodal HA protocol consists of intravenous ketorolac, a PENG block, general endotracheal anesthesia, 4 mg of dexamethasone, 25 mg of ketamine at induction and 25 mg of ketamine slowly infused throughout the case, and post-free HA. We have a 100% same-day discharge rate, with no reported block complications and no groin complications, and for us, this method has proved to decrease the time to discharge.
  • ||||||||||  paclitaxel / Generic mfg.
    Enrollment open, Trial initiation date, Metastases:  A Phase I/II Study of Intraperitoneal Paclitaxel in Patients With Metastatic Appendiceal Adenocarcinoma (clinicaltrials.gov) -  Jan 31, 2024   
    P1/2,  N=39, Recruiting, 
    We have a 100% same-day discharge rate, with no reported block complications and no groin complications, and for us, this method has proved to decrease the time to discharge. Not yet recruiting --> Recruiting | Initiation date: Jun 2024 --> Jan 2024
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Cortistatin prevents glucocorticoid-associated osteonecrosis of the femoral head via the GHSR1a/Akt pathway. (Pubmed Central) -  Jan 31, 2024   
    Furthermore, osteoblast and endothelial cells were cultured and stimulated with dexamethasone (Dex) in the presence or absence of recombinant CST...Moreover, blocking GHSR1a, a well-accepted receptor of CST, or blocking the AKT signaling pathway largely abolished the protective function of CST in Dex-induced disorder of the cells. Taken together, we indicate that CST has the capability to prevent GC-induced apoptosis and metabolic disorder of osteoblasts in the pathogenesis of ONFH via the GHSR1a/AKT signaling pathway.
  • ||||||||||  hydrocortisone / Generic mfg.
    Journal, IO biomarker:  Hydrocortisone cardioprotection in ischaemia/reperfusion injury involves antioxidant mechanisms. (Pubmed Central) -  Jan 31, 2024   
    Taken together, we indicate that CST has the capability to prevent GC-induced apoptosis and metabolic disorder of osteoblasts in the pathogenesis of ONFH via the GHSR1a/AKT signaling pathway. Our results provide the first evidence that acute HC treatment during early reperfusion induces cardioprotection against AMI, associated with a non-genomic HC-triggered NHE1 inhibition by AKT and antioxidant action that might involves mitochondrial dynamics improvement.
  • ||||||||||  prednisolone / Generic mfg.
    Enrollment open:  PREMI: Prednisolone Administration in Patients With Unexplained REcurrent MIscarriages (clinicaltrials.gov) -  Jan 31, 2024   
    P2,  N=490, Recruiting, 
    Our results provide the first evidence that acute HC treatment during early reperfusion induces cardioprotection against AMI, associated with a non-genomic HC-triggered NHE1 inhibition by AKT and antioxidant action that might involves mitochondrial dynamics improvement. Not yet recruiting --> Recruiting
  • ||||||||||  triamcinolone acetonide / Generic mfg., pimecrolimus topical / Generic mfg.
    Review, Journal:  Non-Systemic Medication for the Treatment of Prurigo Nodularis: A Systematic Review. (Pubmed Central) -  Jan 31, 2024   
    There was 1 study each on topical pimecrolimus, tacrolimus, 2% dinitrochlorobenzene, cryotherapy, acupuncture, and the Paul Gerson Unna boot...Phototherapy is likely effective, but the risk of relapse is high. Cryotherapy may also be a lesion-directed agent to circumvent challenges to adherence and avoidance of systemic medication.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Subsequent therapy and outcomes in patients with newly diagnosed multiple myeloma experiencing disease progression after quadruplet combinations. (Pubmed Central) -  Jan 31, 2024   
    The combination of anti-CD38 monoclonal antibodies to a proteasome inhibitor, an immunomodulatory agent and dexamethasone (quadruplet-QUAD) in sequence with autologous stem cell transplantation (ASCT) leads to deep and durable responses in newly diagnosed multiple myeloma (NDMM)...Median PFS on the next therapy was 2.5?months (95% CI 1.5-3.4) for those with progression <18?months and 7.0 months (95% CI 3.6-10.5) for those with progression ?18?months. Efforts should focus on the early deployment of therapies with new mechanism of action for patients experiencing treatment failure after QUADs.
  • ||||||||||  Paxlovid (nirmatrelvir/ritonavir) / Pfizer
    Review, Journal:  Treatments for COVID-19. (Pubmed Central) -  Jan 30, 2024   
    Immunomodulatory therapies, such as dexamethasone and interleukin-6 or Janus kinase inhibitors, are most useful in severe disease or critical illness...Expected final online publication date for the Annual Review of Medicine, Volume 75 is January 2024. Please see http://www.annualreviews.org/page/journal/pubdates for revised estimates.
  • ||||||||||  methylprednisolone oral / Generic mfg., cyclosporin A microemulsion / Generic mfg.
    Clinical, Review, Journal:  Comparison of Different Treatment Regimens for Long-term Improvement of Renal Function in Patients with Henoch-Sch (Pubmed Central) -  Jan 30, 2024   
    Please see http://www.annualreviews.org/page/journal/pubdates for revised estimates. Regimes based on the administration of prednisolone (either oral or injectable, either as a single drug or as a combination) lead to long-term improvement of renal function in patients with HSP, but the use of other immunosuppressive drugs such as cyclosporine A, of course, with optimizing the drug dose can lead to a significant improvement in the clinical performance.
  • ||||||||||  dexamethasone / Generic mfg., ketamine / Generic mfg.
    Journal:  The HPA Axis as Target for Depression. (Pubmed Central) -  Jan 30, 2024   
    However, as HPA axis alterations occur only in a subset of patients, specific treatment approaches that target only single components of the HPA axis will be effective only in this subset of patients. Companion tests that measure the function of the HPA axis and identify patients with an impaired HPA axis, such as the dexamethasone-corticotrophin-releasing hormone (dex-CRH) test or the molecular dexamethasone- suppression (mDST) test, may match the patient with an effective treatment to enable patient-tailored treatments in terms of a precision medicine approach.
  • ||||||||||  dexamethasone / Generic mfg.
    Enrollment closed:  Dex-Fib: Dexamethasone for Post Uterine Artery Embolization Pain (clinicaltrials.gov) -  Jan 30, 2024   
    P3,  N=82, Active, not recruiting, 
    Companion tests that measure the function of the HPA axis and identify patients with an impaired HPA axis, such as the dexamethasone-corticotrophin-releasing hormone (dex-CRH) test or the molecular dexamethasone- suppression (mDST) test, may match the patient with an effective treatment to enable patient-tailored treatments in terms of a precision medicine approach. Recruiting --> Active, not recruiting
  • ||||||||||  dexamethasone / Generic mfg.
    Preclinical, Journal:  In vitro inflammatory multi-cellular model of osteoarthritis. (Pubmed Central) -  Jan 30, 2024   
    We also investigated response changes following the administration of dexamethasone (DEX) or mesenchymal stromal cell (MSC) treatment via a combination of gene expression and secretory changes, reflecting not only inflammation, but also chondrocyte function...Our results highlight the importance of considering multi-cellular interactions when studying complex systems such as the articular joint. In addition, our approach, using a panel of both inflammatory and chondrocyte functional genes, provides a more comprehensive approach to investigate disease biomarkers, and responses to treatment.
  • ||||||||||  Enrollment open:  Effect of Pericapsular Nerve Block on the Quality of Recovery After Shoulder Arthroscopy (clinicaltrials.gov) -  Jan 30, 2024   
    P=N/A,  N=60, Recruiting, 
    In addition, our approach, using a panel of both inflammatory and chondrocyte functional genes, provides a more comprehensive approach to investigate disease biomarkers, and responses to treatment. Not yet recruiting --> Recruiting
  • ||||||||||  lestaurtinib (CEP-701) / Teva, Kyowa Kirin
    Journal:  Integrating Transcriptomic and Structural Insights: Revealing Drug Repurposing Opportunities for Sporadic ALS. (Pubmed Central) -  Jan 29, 2024   
    Additionally, docking analysis revealed NOS3 as the gene that interacts with all the short-listed drugs, suggesting its possible involvement in the mechanisms underlying the therapeutic potential of these drugs in sporadic ALS. Overall, our study provides a systematic framework for identifying potential drug candidates for sporadic ALS therapy and highlights the potential of drug repurposing as a promising strategy for discovering new therapies for neurodegenerative diseases.
  • ||||||||||  dexamethasone / Generic mfg., levetiracetam / Generic mfg.
    Journal:  Exoscopic resection of a parasagittal atypical meningioma. (Pubmed Central) -  Jan 29, 2024   
    She awoke with a stable examination in the intensive care unit and worked with physical therapy on postoperative day 1. The video can be found here: https://stream.cadmore.media/r10.3171/2023.10.FOCVID23164.
  • ||||||||||  dexamethasone / Generic mfg.
    Biomarker, Retrospective data, Journal, Adverse events, Checkpoint inhibition, PD(L)-1 Biomarker, IO biomarker:  Predictive biomarkers for immune-related adverse events in cancer patients treated with immune-checkpoint inhibitors. (Pubmed Central) -  Jan 29, 2024   
    Gender, antibiotic use, post-treatment NLR, and baseline CTC level are potential predictive biomarkers of irAEs, while baseline PNI, BMI, and post-treatment LDH may predict the severity of irAEs. The predictive effect of irAE occurrence on survival benefit may depend on the type of irAE.